Advertisement
Canada markets closed
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7296
    -0.0001 (-0.02%)
     
  • CRUDE OIL

    82.81
    0.00 (0.00%)
     
  • Bitcoin CAD

    87,999.72
    -2,929.23 (-3.22%)
     
  • CMC Crypto 200

    1,383.69
    -40.41 (-2.84%)
     
  • GOLD FUTURES

    2,329.10
    -9.30 (-0.40%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,476.25
    -188.25 (-1.07%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Ionis Pharmaceuticals’ Revenue Growth Rate

Ionis Pharmaceuticals’ Revenue Growth Rate

Ionis Pharmaceuticals (IONS), a leading biopharmaceutical company, has developed a variety of drugs for the treatment of life-threatening diseases through its broadly applicable drug discovery platform. Ionis reported earnings per share of -$0.29 on revenues of $117.7 million during the second quarter, reporting year-over-year growth of 5.0% during the quarter. The chart below compares the company’s revenues since the first quarter of 2017.